GSK GlaxoSmithKline PLC

+0.01  (+0%)
Previous Close 40.54
Open 40.2
Price To Book 17.94
Market Cap 100663803809
Shares 2,482,461,253
Volume 2,279,318
Short Ratio 2.95
Av. Daily Volume 3,772,777

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
First-line ovarian cancer
FDA Approval announced July 23, 2018.
Approval announced April 24, 2018 for expanded label.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
Approval announced December 12, 2017.
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Phase 1/2 data due 1H 2019.
Niraparib - AVANOVA
Ovarian cancer
Phase 3 data due 2H 2020.
Severe hypereosinophilic syndrome (HES)
Phase 1/2 trial ongoing. Data at ASCO 2018 noted ORR 25%.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Approval announced January 11, 2018.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data due 2H 2019.
Niraparib - PRIMA
First-line ovarian cancer
Approval announced September 18, 2017.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Approval announced November 21, 2017.
Dolutegravir + rilpivirine
Advisory Committee July 25, 2018 voted 3-16 against recommending approval. CRL issued September 7, 2018.
Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype
NDA filing submitted October 18, 2018. PDUFA date April 17, 2019 assuming priority review.
Dolutegravir + lamivudine
Phase 3 data due 2H 2020.
Daprodustat - ASCEND-D
Phase 3 data due 2H 2020.
Development discontinued due to lack of efficacy.
Chronic obstructive pulmonary disease (COPD)
Approval announced October 20, 2017.
Approval announced July 21, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)
Phase 3 data due 1H 2019.
Closed Triple - CAPTAIN
Approval announced September 19, 2017.
Closed Triple
CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 top-line data released April 24, 2018. Primary endpoint met. sNDA to be potentially filed 2H 2018.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 1 data to be presented 1H 2019.
Endometrial cancer
Phase 3 data positive data released October 30, 2018.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Phase 2 data due 1H 2020.
GSK 165
Phase 2 additional data due 1H 2019.
Niraparib - JASPER
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2020.
Benlysta (belimumab) and rituximab
Systemic lupus erythematosus (SLE)
Phase 2b released October 21, 2018 did not meet primary endpoint.
Rheumatoid Arthritis
Phase 1 data at SITC Novemeber 2018 - 15% ORR for high dose , 9% ORR for lower dose.
TSR-022 + TSR-042 AMBER
Solid tumors
Phase 2 data due late-2019.
Niraparib + bevacizumab OVARIO
Ovarian cancer
Phase 1 trial ongoing.
Solid tumors
Phase 3 data due 1H 2020.
Mepolizumab - SYNAPSE
Nasal polyps
Phase 3 data due 2H 2019.
GSK’916 (BCMA)
Multiple myeloma
sBLA filing announced November 19, 2018.
Severe eosinophilic asthma - pediatric
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer

Latest News

  1. [$$] U.K. Closes Corruption Probes of GlaxoSmithKline, Rolls-Royce Individuals
  2. British fraud office abandons Rolls-Royce, GSK investigations
  3. Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
  4. Top Ranked Income Stocks to Buy for February 22nd
  5. Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
  6. Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
  7. Merck Gets Priority Review for Keytruda in Third-Line SCLC
  8. Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
  9. [$$] Drug Maker Pernix Therapeutics Files for Bankruptcy, Blaming Competition From Generics
  10. Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
  11. New Strong Buy Stocks for February 19th
  12. What Analysts Are Recommending for Teva Pharmaceutical This Month
  13. Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc.
  14. What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
  15. Top Ranked Growth Stocks to Buy for February 15th
  16. Comparing Dividends and Tax Rates for MRK and GSK in 2019
  17. Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?
  18. Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
  19. Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up